Skip to main content
European Commission logo print header
Contenu archivé le 2022-12-23

Assessment of the Impact of Improved Local Control by Radiotherapy on survival Cancer Patients

Objectif



The general objective of the proposed concerted action is to make improvements in radiotherapy accessible for each patient in each country in Europe. This goal will be pursued by initiating clinical trials and instruction of national reference centres with the following aims.
1. To investigate the therapeutic gain that can be achieved by adapting the individual irradiation fractionation scheme to the tumour growth rate. 2. To investigate the possibility of improving local control, survival and reducing serious side effects by comparing different dose levels of radiation.
3. Designing protocols for controlling treatment accuracy with the help of portal imaging and searching for causes of inaccuracies in the treatment chain.

Project outline:
1. Trial A: fractionation studies in head and neck cancer. A randomized phase lll trial will be executed in which all patients will be injected with lUdR and biopsied prior to radiotherapy in order to assess the potential tumour doubling time. The patients will then be stratified and randomized according to the tumour growth rate. Within this trial the known advantages of different fractionation schedules will be further exploited. 2. Trial B: dose-effect study in breast cancer. A randomized phase lll clinical trial will be executed comparing: a) conventional irradiation treatment b) 10% higher radiation dose to the primary tumour area 3. Control of treatment accuracy. Standard protocols for measurement and control of the treatment accuracy through the use of portal films and electronic portal imaging devices will be developed. Software and instruction for the analysis of portal films and images obtained with an electronic portal imaging device developed in the central coordinating centre will be made available to the participating centres to analyse treatment deviations.

Appel à propositions

Data not available

Régime de financement

CSC - Cost-sharing contracts

Coordinateur

THE NETHERLANDS CANCER INSTITUTE/ANTONI VAN LEEUWENHOEK HOSPITAL
Contribution de l’UE
Aucune donnée
Adresse
121,Plesmanlaan 121
1066 CX AMSTERDAM
Pays-Bas

Voir sur la carte

Coût total
Aucune donnée

Participants (2)